The DOJ's April 23, 2026 Final Order placing state-licensed medical cannabis in Schedule III of the Controlled Substances Act was historic on its own terms - but what followed in the next five days may matter just as much. With the order formally published in the Federal Register on April 28, a cascade of deadlines has now been set in motion, and the window for operators to act under favorable conditions is measured in weeks, not months.
From Announcement to Effective Law: What Publication Actually Triggers
Federal Register publication is, in this context, more than a formality. April 28 is the legal effective date of the rescheduling - the moment cannabis covered by a state medical marijuana license formally ceased to be a Schedule I controlled substance and became Schedule III. That single date starts at least two clocks running simultaneously.
The first: a 60-day window for expedited DEA registration applications closes on June 26, the final business day before June 29 - which is, not coincidentally, when the formal rulemaking hearing begins. The alignment is deliberate. The second clock: anyone wishing to participate in that broader hearing must file notice of intent by May 24 electronically, or postmarked by May 20 by mail. The DEA will notify selected participants on June 22.
Also published on April 28 was the formal withdrawal of the prior hearing proceedings initiated in August 2024 - proceedings that had been suspended since January 2025 after the presiding administrative law judge retired. The DEA's reasoning was straightforward: a fresh start was faster than resurrecting a dormant process. That judgment reflects the explicit mandate of Executive Order 14370, which directed the rescheduling to proceed expeditiously.
The Hearing That Must Finish by July 15
The new Notice of Hearing targets the broader question the April 23 order deliberately left open: whether all marijuana - not just state-licensed medical cannabis - should move from Schedule I to Schedule III. The hearing begins June 29 at 9:00 a.m. ET at the DEA Hearing Facility in Arlington, Virginia, and the notice specifies it must conclude no later than July 15, 2026. A two-and-a-half-week deadline for a proceeding of this magnitude is compressed by any measure of federal administrative practice.
Here's the catch for anyone who participated in the 2024 proceedings: prior submissions don't carry over. Every interested party must resubmit under the new notice. That requirement may feel redundant to veterans of the earlier process, but it reflects the legal reality that the prior proceedings have been formally terminated - a clean slate, procedurally speaking.
The Tax Implications Are Substantial, and Guidance Is Coming
For cannabis businesses, Section 280E of the Internal Revenue Code has functioned for years as a punishing structural disadvantage. Because 280E prohibits deductions and credits for businesses trafficking in Schedule I or II controlled substances, operators have been taxed on gross revenue rather than net income - effectively paying federal taxes on money they never kept. Rescheduling to Schedule III removes that bar for state-licensed medical cannabis operations.
Treasury and the IRS confirmed on April 23 that formal guidance is forthcoming. The expected content is worth reading carefully. For businesses with mixed activities, the guidance is expected to clarify that 280E applies only to the Schedule I or II trafficking portions - meaning expense apportionment becomes a real planning tool. More significantly, a transition rule is anticipated: rescheduling will generally be treated as applying for the full taxable year that includes the April 28 effective date. The Final Order went further still, explicitly encouraging Treasury to consider retrospective relief for prior taxable years in which a state licensee operated lawfully under state law. That language doesn't create an entitlement, but it signals intent - and operators with significant prior 280E exposure should be watching the guidance closely.
The Registration Portal and What Operators Should Prepare Now
The DEA's Medical Marijuana Dispensary Registration Portal opened April 29. The $794 annual application fee is, for the moment, payable only via PayPal - an oddly specific constraint that the agency says will be broadened in coming weeks. The application itself spans seven sections and is more demanding than a routine business registration; operators should not treat it as something to complete in an afternoon.
The most substantive requirements sit in Section 5. Applicants must identify intended suppliers by DEA registration number, confirm the existence of standard operating procedures across a broad range of compliance functions - ordering, storage, security, dispensing, destruction, theft reporting - and provide personal identifying information, including dates of birth and Social Security numbers, for every individual expected to have access to controlled substances. Security infrastructure at each location must also be described in detail.
The 60-day filing window carries real operational value. Under the Final Order, applicants who submit within that window - by approximately June 27 - may continue operating under their state licenses while federal review is pending. That safe harbor matters because federal DEA registration is now required for entities handling Schedule III controlled substances; without it, or without the protection of the expedited pathway, the legal footing for continued operations becomes less certain. To put it plainly: filing early isn't just administratively convenient, it's a risk management decision.
The broader framework the Final Order establishes - treating state medical marijuana licenses as conclusive evidence of state-law authorization, relying on existing state regulatory infrastructure rather than building a parallel federal system - reflects a cooperative-federalism design that has been debated in cannabis policy circles for years. Whether it holds up under the scrutiny of the June 29 hearing, and what shape the final rule takes for recreational cannabis, remains to be seen. For now, the medical cannabis industry has its clearest federal legal footing ever. The question is whether operators can organize quickly enough to use it.
